This agreement is said to make Siemens Medical Solutions Diagnostics the first in vitro diagnostics distributor of an automated TSH receptor antibody (TRAb) assay featuring stimulating TRAb KreLo antibodies, which are specific to the diagnosis of Graves’ disease.
Studies have shown that the TRAb test has the highest diagnostic power to differentiate Graves’ disease from toxic nodular goiters.
Joe Bernardo, senior vice president, central lab testing, Siemens Medical Solutions Diagnostics, said: “The new TRAb assay has enormous potential to help diagnose, monitor and predict the course of Graves’ disease.”